← Leaderboards
Andrew L Wolfe
University Of California, San Francisco
$1,146,361
Attributed
$1,146,361
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249K · FY2018–23$250K$187.5K$125K$62.5K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,146,361 · 2
By mechanism
R00$747,000 · 1
K99$399,361 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Eric Collisson$14,159,893
- Nadav Ahituv$31,471,722
- Martin Kampmann$17,201,095
- Jean-Philippe Francois Marie Coppe$2,137,183
- James Bayrer$4,737,144
Others in their field
Other Emerging Leaders on “Ablation”
- James Jeffrey Sahn · 4e Therapeutics Inc.$7,064,669
- Kenneth B. Bader · University Of Chicago$6,109,156
- John R Lukens · University Of Virginia$5,842,869
- Juliette Elizabeth McGregor · University Of Rochester$5,567,728
- Jie Shen · Washington University$5,388,462
- Ashley E Webb · Brown University$5,147,077
Research focus
AblationAdvisory CommitteesAnticancer ResearchAddictionAutomobile DrivingBindingBiologicalBiologyCancer Cell LineAntineoplastic AgentsCancer TypeCareer DevelopmentCell LineCell MembraneCellsCell SurvivalCollaborationsCombined Modality TherapyCourse DevelopmentCrispr InterferenceCancer RegressionDegradation PathwayDependenceDesign
Grant awards (6)
Cellular mechanisms and therapeutic possibilities of inhibiting oncogenic KRAS$249,000
R00 · FY2023 · CA · contact PI
Cellular mechanisms and therapeutic possibilities of inhibiting oncogenic KRAS$249,000
R00 · FY2022 · CA · contact PI
Cellular mechanisms and therapeutic possibilities of inhibiting oncogenic KRAS$249,000
R00 · FY2021 · CA · contact PI
Cellular mechanisms and therapeutic possibilities of inhibiting oncogenic KRAS$129,145
K99 · FY2020 · CA · contact PI
Cellular mechanisms and therapeutic possibilities of inhibiting oncogenic KRAS$135,108
K99 · FY2019 · CA · contact PI
Cellular mechanisms and therapeutic possibilities of inhibiting oncogenic KRAS$135,108
K99 · FY2018 · CA · contact PI